Funding Opportunity: Clinical Sites for the HIV/Cervical Cancer Prevention “CASCADE”

Focus areas of the HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network
Originally published by the National Cancer Institute

Through this Funding Opportunity Announcement (FOA) RFA-CA-22-051, the National Cancer Institute (NCI) solicits applications from institutions/organizations to participate as Clinical Sites for the HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network. The ‘CASCADE’ Network will conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. ‘CASCADE’ clinical trials will be conducted in intended-use environments in resource-constrained settings in low and middle-income countries and in regions with health disparities in the United States, and will have four major scientific focus areas: increasing screening uptake, improving the management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments for cervical cancer prevention in women living with HIV. Evidence from these trials is expected to inform clinical practice guidelines and improve the implementation of cervical cancer prevention and control programs globally.

‘CASCADE’ will consist of three organizational components each with its own FOA: U24 Coordinating Center (funded previously by RFA-CA-21-045), UG1 Research Bases (funded previously by RFA-CA-21-046), and UG1 Clinical Sites. Three UG1 Clinical Sites have previously been funded under RFA-CA-21-047; five additional UG1 Clinical Sites will be supported under this FOA to join the ‘CASCADE’ Network.

As an integral part of this Cooperative Agreement-funded network, the UG1 Clinical Sites (this FOA) will provide a pluripotent infrastructure for accruing participants to network clinical trials, interface with the UG1 Research Bases and U24 Network Coordinating Center during concept and protocol development to provide insights and input on clinical significance and study feasibility and provide on-site operational leadership for the successful conduct of the network clinical trials.

For more information: “Launching ‘CASCADE’: A Clinical Trials Network to Optimize Cervical Cancer Screening and Precancer Treatment for the Vulnerable Population of Women Living With HIV was originally published by the National Cancer Institute.”